Syndax Pharmaceuticals Inc·4

Mar 3, 4:24 PM ET

Madigan Catherine 4

4 · Syndax Pharmaceuticals Inc · Filed Mar 3, 2022

Insider Transaction Report

Form 4
Period: 2022-03-01
Madigan Catherine
Chief Medical Officer
Transactions
  • Award

    Stock Options (Right to buy)

    2022-03-01$16.06/sh+180,000$2,890,800180,000 total
    Exercise: $16.06Exp: 2032-03-01Common Stock (180,000 underlying)
Footnotes (1)
  • [F1]Twenty five percent (25%) of the total number of shares underlying the option shall vest on March 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT